MacroGenics to Participate in Upcoming Investor Conference
02 Fevereiro 2024 - 6:30PM
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical
company focused on developing, manufacturing and commercializing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, today announced that the Company's management will
participate in the following upcoming investor conference:
- Guggenheim Healthcare Talks | 6th Annual Biotechnology
Conference (New York). MacroGenics’ President and
CEO, Scott Koenig, M.D., Ph.D., will participate in a fireside chat
on Wednesday, February 7, 2024, at 2:00 pm ET. MacroGenics’
management will also participate in one-on-one meetings.
A webcast of the above presentation may be accessed under
"Events & Presentations" in the Investor Relations section of
MacroGenics' website at http://ir.macrogenics.com/events.cfm.
The Company will maintain an archived replay of this webcast on its
website for 30 days.
About MacroGenics,
Inc.MacroGenics (the Company) is a biopharmaceutical
company focused on developing, manufacturing and commercializing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer. The Company generates its pipeline of product candidates
primarily from its proprietary suite of next-generation
antibody-based technology platforms, which have applicability
across broad therapeutic domains. The combination
of MacroGenics' technology platforms and protein
engineering expertise has allowed the Company to generate promising
product candidates and enter into several strategic collaborations
with global pharmaceutical and biotechnology companies. For more
information, please see the Company's website
at www.macrogenics.com. MacroGenics and
the MacroGenics logo are trademarks or registered
trademarks of MacroGenics, Inc.
###
CONTACTS:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172, info@macrogenics.com
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MacroGenics (NASDAQ:MGNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024